Status:

COMPLETED

Safety and Efficacy of L-NAME and Midodrine to Increase MAP

Lead Sponsor:

US Department of Veterans Affairs

Conditions:

Orthostatic Hypotension

Spinal Cord Injury

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

After a spinal cord injury the brain is no longer completely in control of the body below the level of injury. This affects many organs and systems in the body, we are interested in understanding how ...

Detailed Description

Blood pressure regulation is compromised in persons with tetraplegia due to de-centralization of sympathetic cardiovascular control, associated with hypotension during upright positioning (7, 10, 18, ...

Eligibility Criteria

Inclusion

  • Spinal Cord Injured Subjects:
  • chronic spinal cord injury (1 year post injury) with a seated MAP of 65mmHg (almost all individuals with tetraplegia demonstrate this)
  • Male or female with an age of 18 - 65 years
  • Control Subjects:
  • Male or female with an age of 18 - 65 years

Exclusion

  • Spinal Cord Injured Subjects:
  • acute illness
  • cardiovascular disease
  • renal disease
  • medications that affect the cardiovascular system
  • Control Subjects:
  • acute illness
  • cardiovascular disease
  • renal disease
  • medications that affect the cardiovascular system

Key Trial Info

Start Date :

May 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2013

Estimated Enrollment :

34 Patients enrolled

Trial Details

Trial ID

NCT00835224

Start Date

May 1 2010

End Date

August 1 2013

Last Update

April 23 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

VA Medical Center, Bronx

The Bronx, New York, United States, 10468